Daily Treatment with Sildenafil Reverses Endothelial Dysfunction and Oxidative Stress in an Animal Model of Insulin Resistance

European Urology

Volumn 53, Issue 6, 2008, Pages 1272-1281

  Behr Roussel, Delphine ^a   Oudot, Alexandra ^a   Caisey, Stéphanie ^a   Coz, Olivier L E ^a   Gorny, Diane ^a   Bernabé, Jacques ^a   Wayman, Chris ^b   Alexandre, Laurent ^a   Giuliano, François A ^c  

^a CNRS   (France)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

Endothelium; Insulin resistance; Oxidative stress; Sildenafil; Vascular function

Indexed keywords

8 ISOPROSTANE; ACETYLCHOLINE; CALCIMYCIN; CYCLIC GMP; FRUCTOSE; GLUCOSE; INTERLEUKIN 6; NITRATE; NITRITE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; SILDENAFIL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; FEEDING; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; MESENTERIC ARTERY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION; VASODILATATION;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM; INSULIN RESISTANCE; MALE; OXIDATIVE STRESS; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; RATS; RATS, WISTAR; SULFONES;

EID: 42949165933     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.11.018     Document Type: Article

References (36)

1. Nilsson P.M., Engstrom G., and Hedblad B. The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects-population-based study comparing three different definitions. Diabet Med 24 (2007) 464-472
2. Baron A.D. Vascular reactivity. Am J Cardiol 84 (1999) 25J-27J
3. Anderson T.J., Uehata A., Gerhard M.D., et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 26 (1995) 1235-1241
4. Elliott S.S., Keim N.L., Stern J.S., Teff K., and Havel P.J. Fructose, weight gain, and the insulin resistance syndrome. Am J Clin Nutr 76 (2002) 911-922
5. Kawasaki T., Ogata N., Akanuma H., et al. Postprandial plasma fructose level is associated with retinopathy in patients with type 2 diabetes. Metabolism 53 (2004) 583-588
6. Galipeau D., Arikawa E., Sekirov I., and McNeill J.H. Chronic thromboxane synthase inhibition prevents fructose-induced hypertension. Hypertension 38 (2001) 872-876
7. Verma S., Skarsgard P., Bhanot S., et al. Reactivity of mesenteric arteries from fructose hypertensive rats to endothelin-1. Am J Hypertens 10 (1997) 1010-1019
8. Reed M.J., Ho H., Donnelly R., and Reaven G.M. Salt-sensitive and carbohydrate-sensitive rodent hypertension: evidence of strain differences. Blood Press 3 (1994) 197-201
9. Behr-Roussel D., Gorny D., Mevel K., et al. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur Urol 47 (2005) 87-91
10. Hurt K.J., Musicki B., Palese M.A., et al. Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection. Proc Natl Acad Sci U S A 99 (2002) 4061-4066
11. Dimmeler S., Fleming I., Fisslthaler B., et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399 (1999) 601-605
12. Musicki B., Champion H.C., Becker R.E., et al. Erection capability is potentiated by long-term sildenafil treatment: role of blood flow-induced endothelial nitric-oxide synthase phosphorylation. Mol Pharmacol 68 (2005) 226-232
13. Rosano G.M.C., Aversa A., Vitale C., et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 47 (2005) 214-222
14. Gopaul N.K., Manraj M.D., Hebe A., et al. Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism. Diabetologia 44 (2001) 706-712
15. Sonnenberg G.E., Krakower G.R., and Kissebah A.H. A novel pathway to the manifestations of metabolic syndrome. Obes Res 12 (2004) 180-186
16. Patrono C., and FitzGerald G.A. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 17 (1997) 2309-2315
17. Nichols D.J., Muirhead G.J., and Harness J.A. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 53 Suppl 1 (2002) 5S-12S
18. Katakam P.V., Ujhelyi M.R., Hoenig M.E., and Miller A.W. Endothelial dysfunction precedes hypertension in diet-induced insulin resistance. Am J Physiol 275 (1998) R788-R792
19. Miatello R., Risler N., Castro C., et al. Aortic smooth muscle cell proliferation and endothelial nitric oxide synthase activity in fructose-fed rats. Am J Hypertens 14 (2001) 1135-1141
20. Richey J.M., Si X., Halter J.B., and Webb R.C. Fructose perfusion in rat mesenteric arteries impairs endothelium-dependent vasodilation. Life Sci 62 (1998) L55-L62
21. Giugliano F., Esposito K., Di Palo C., et al. Erectile dysfunction associates with endothelial dysfunction and raised proinflammatory cytokine levels in obese men. J Endocrinol Invest 27 (2004) 665-669
22. Kusterer K., Pohl T., Fortmeyer H.P., et al. Chronic selective hypertriglyceridemia impairs endothelium-dependent vasodilatation in rats. Cardiovasc Res 42 (1999) 783-793
23. Wang X., Hattori Y., Satoh H., et al. Tetrahydrobiopterin prevents endothelial dysfunction and restores adiponectin levels in rats. Eur J Pharmacol 555 (2007) 48-53
24. Suto T., Losonczy G., Qiu C., et al. Acute changes in urinary excretion of nitrite + nitrate do not necessarily predict renal vascular NO production. Kidney Int 48 (1995) 1272-1277
25. Behr-Roussel D., Rupin A., Simonet S., Fabiani J., and Verbeuren T.J. Urinary nitrate excretion in cholesterol-fed rabbits: effect of a chronic treatment by N-iminoethyl-L-lysine, a selective inhibitor of inducible nitric oxide synthase. Eur J Pharmacol 388 (2000) 275-279
26. Ulker S., McMaster D., McKeown P.P., and Bayraktutan U. Impaired activities of antioxidant enzymes elicit endothelial dysfunction in spontaneous hypertensive rats despite enhanced vascular nitric oxide generation. Cardiovasc Res 59 (2003) 488-500
27. Cave A.C., Brewer A.C., Narayanapanicker A., et al. NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 8 (2006) 691-728
28. Kapur S., Bedard S., Marcotte B., Cote C.H., and Marette A. Expression of nitric oxide synthase in skeletal muscle: a novel role for nitric oxide as a modulator of insulin action. Diabetes 46 (1997) 1691-1700
29. Muzaffar S., Shukla N., Srivastava A., Angelini G.D., and Jeremy J.Y. Sildenafil citrate and sildenafil nitrate (NCX 911) are potent inhibitors of superoxide formation and gp91phox expression in porcine pulmonary artery endothelial cells. Br J Pharmacol 146 (2005) 109-117
30. Ghofrani H.A., Voswinckel R., Reichenberger F., et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 44 (2004) 1488-1496
31. Morano S., Mandosi E., Fallarino M., et al. Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. Eur Urol 52 (2007) 1768-1776
32. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1993) 801-809
33. Burnett A.L., Strong T., Musicki B., Bivalacqua T.J., and Jin L. Serum biomarkers of endothelial function and oxidative stress after daily dosing of sildenafil in type 2 diabetic men with erectile dysfunction. J Urology 177 (2007) 955
34. Bella A.J., Deyoung L.X., Al Numi M., and Brock G.B. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Eur Urol 52 (2007) 990-1005
35. Hatzimouratidis K., and Hatzichristou D. Phosphodiesterase type 5 inhibitors: the day after. Eur Urol 51 (2007) 75-88
36. Ückert S., Hedlund P., Andersson K.E., et al. Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol 50 (2006) 1194-1207